The Liver Institute at Methodist Dallas — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$182,799	191
2023	Research	$13,616	1
2021	Research	$1,291	1
2020	Research	$304	3
2019	Research	$475	6

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim International GmbH $182,799 191 payments
Bausch Health US, LLC $13,616 1 payment
Merck Sharp & Dohme Corporation $2,069 10 payments

Studies the money was for Research payments · program years 2019–2025

Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis due to MASH: a Phase IIa, multi-center, randomized, double-blind, placebo-controlled trial $164,363 132 payments
MRD/PoCP study in NFLD (12 wks) $18,436 59 payments
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis $13,616 1 payment
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial $1,291 1 payment
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial $778 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.